Also trades as: ROIVW (NASDAQ) · $vol 0M
ROIV NASDAQ
Roivant Sciences Ltd.
1W: -4.0%
1M: -3.0%
3M: +2.7%
YTD: +28.6%
1Y: +161.4%
3Y: +209.7%
5Y: +185.2%
$32.55
+4.34 (+15.38%)
Weekly Expected Move ±4.2%
$27
$28
$29
$31
$32
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$20.2B
52W Range10.594-30.33
Volume3,769,587
Avg Volume5,524,254
Beta1.14
Dividend—
Analyst Ratings
Company Info
CEOMatthew Gline
Employees908
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-08
Websiteroivant.com
11-12 St. James's Square
London SW1Y 4LB
GB
London SW1Y 4LB
GB
44 2074 003 347
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest News
S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Earnings Scheduled For May 20, 2026
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Venker Eric | M-Exempt | 200,000 | $3.85 | 2026-04-20 |
| Venker Eric | M-Exempt | 200,000 | $3.85 | 2026-04-20 |
| Venker Eric | S-Sale | 200,000 | $29.59 | 2026-04-20 |
| Pulik Richard | A-Award | 60,644 | — | 2026-04-20 |
| Pulik Richard | A-Award | 84,026 | $29.08 | 2026-04-20 |